

RECKITT BENCKISER GROUP PLC

2025 SHARE BUYBACK PROGRAMME
COMPLETION OF FIRST TRANCHE AND COMMENCEMENT OF SECOND TRANCHE

Reckitt Benckiser Group plc ("Reckitt" or the "Company") confirms the successful completion of the first tranche of £250m (the "First Tranche") of its 2025 £1 billion share buyback programme (the "Programme") announced on 24 July 2025.

Under the First Tranche, between 28 July 2025 and 21 October 2025, the Company has purchased 4,445,840 ordinary shares of 10p each (the "Ordinary Shares") at an average price of £56.23, and which have been cancelled.

Further to the announcement on 26 September 2025, the Company confirms that the second tranche of the Programme (the "Second Tranche") to return a further up to £250 million of capital to shareholders, will commence on 22 October 2025 and will end on or before 30 January 2026. As previously announced, the purpose of the Second Tranche is to reduce the share capital of the Company. The Second Tranche will take place within the limitations of the authority granted to the Board by shareholders at the Company's Annual General Meeting on 8 May 2025. Pursuant to that authority, the maximum number of shares which remain available for purchase under the Second Tranche is 63,954,160.

As previously announced, Reckitt has entered into an agreement with BNP Paribas under which it has instructed BNP Paribas to manage the Second Tranche of the Programme. BNP Paribas will, acting as riskless principal, purchase Ordinary Shares for an aggregate purchase price of no greater than £250 million and will simultaneously sell such Ordinary Shares on to the Company. To the extent permitted by law, Ordinary Shares purchased under the Second Tranche of the Programme will be held in treasury until completion of the Second Tranche, at which time they will be cancelled.

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

CONTACT DETAILS:

Nick Ashworth +44 (0)7408 812350

Investor Relations Director

Catheryn O'Rourke +44 (0) 1753 217 800

General Counsel & Company Secretary

About Reckitt*:

We make the products people trust to care for the ones they love. We are home to some of the world's best-loved consumer health and hygiene brands, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish and Veet. Consumers are at the heart of everything we do. By creating innovative, science-backed solutions, we support people every day to live healthier lives.

Reckitt exists to protect, heal and nurture in the pursuit of a cleaner, healthier world. This commitment goes beyond the products we make. Through our actions, we expand access to healthcare, education and economic opportunities. We support the planet by reducing waste, conserving resources and driving sustainable innovation.

We believe good health starts at home. With every action we take, we strive to make our consumers' lives easier, cleaner and healthier, to strengthen communities and to create a more sustainable future.

* Reckitt is the trading name of the Reckitt Benckiser group of companies

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCGZMZGNMFGKZM